Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of July 2020, with a report date of July 10, 2020. The document serves as a transaction notification regarding the acquisition of ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) through the Company's Share Reward Plan.
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It exclusively details specific share transactions.
| Transaction Type | Instrument | Price per Share | Total Volume | Transaction Date |
|---|---|---|---|---|
| Acquisition (Dividend Re-investment) | Ordinary Shares (25p each) | £16.1010 | 393 shares | July 9, 2020 |
Note: The total volume of 393 shares is the aggregate of individual transactions listed in the filing.
Material Changes
This filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It is a routine disclosure of insider share acquisitions mandated by regulatory requirements.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transactions were executed on the London Stock Exchange (XLON) and resulted from the re-investment of dividends paid on July 9, 2020.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions were acquisitions of ordinary shares via dividend re-investment, not open-market purchases or sales.
- Participants: Transactions involved 13 individuals, including the CEO (Ms E Walmsley), President of Global Vaccines (Mr R Connor), and other senior executives.
- Share Price: The uniform execution price for all transactions was £16.1010 per share.
- Scope: The filing does not contain financial performance data; investors should refer to Form 20-F or quarterly reports for revenue and earnings information.